Chemocentryx patents expiration

1. Tavneos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8906938 CHEMOCENTRYX C5aR antagonists
Dec, 2029

(6 years from now)

US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(7 years from now)

US11603356 CHEMOCENTRYX Amorphous form of a complement component C5a receptor
May, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
New Chemical Entity Exclusivity (NCE) Oct 7, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 2025-10-07

Market Authorisation Date: 07 October, 2021

Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids


More Information on Dosage

TAVNEOS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic